Insulin ResistanceEarly Phase 1NCT02256865
Hormonal Mechanisms of Sleep Restriction
A Early Phase 1 study testing Ketoconazole, Hydrocortisone and Testosterone in people with Insulin Resistance, run by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center at 1 site in United States.
Trial summary
The purpose of this study is to study the effects of sleep restriction on the production of two hormones, cortisol and testosterone. The investigators aim to show that changing these hormones leads to insulin resistance, which is an important cause of type 2 diabetes mellitus. Read more about this study
- Who is it for?
- Ages 22 to 45 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Insulin Resistance
- What is being tested?
- Ketoconazole, Hydrocortisone and Testosterone
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- Oct 2014to Oct 2023
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 to 45 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Men aged 22-45 years
- Willingness to provide written informed consent
- Stable weight over preceding 6 weeks
- Body Mass index (BMI) 20-28 kg/m2
Who cannot join
- Unable or unwilling to provide IRB-approved informed consent
- Clinical disorders and/or illnesses
- Current medical or drug treatment, as assessed by questionnaire
- History of brain injury or of learning disability
- Vision or hearing impairment unless corrected back to normal
- Anemia (Hct <38%)
Show all 19Show fewer
- History of psychiatric illness
- Clinically significant abnormalities in blood and urine, and free of traces of drugs Other endocrine abnormalities including hypothyroidism or adrenal failure; primary gonadal disease as indicated by serum LH or FSH concentration >10 or >15 IU/L, respectively, hyperprolactinemia indicated by prolactin >25ug/L
- Type 2 Diabetes (HgbA1C)
- Current smoker
- Recent or concurrent drug or alcohol abuse
- Blood donation in previous eight weeks
- Travel across time zones within one month of entering the study
- Sleep or circadian disorder
- Shift work within three months of entering the study
- Irregular bedtimes (not between 6 and 10 hours in duration)
- Unoperated obstructive uropathy, recurrent prostatitis, indeterminate prostatic nodularity, Hx or Suspicion of cancer of the prostate gland or PSA >4ng/ml
- Previous adverse reaction to sleep deprivation or any of the drugs to be administered
- Concurrent participation in another research study
Trial locations and contacts
1 site in 1 country.
United States1 site
Los Angeles Biomedical Research Institute
Torrance, California, 90509
About this study
The purpose of this study is to study the effects of sleep restriction on the production of two hormones, cortisol and testosterone. The investigators aim to show that changing these hormones leads to insulin resistance, which is an important cause of type 2 diabetes mellitus. The investigators may also study the effect of sleep restriction on your food intake and cravings, mood, inflammation, metabolism (including bone), and other hormones. Inflammation is your body's response to stress and injury. Bone metabolism is a process of how your body regenerates (renews) new bone cells and removes old bone cells. Hormones are natural substances (materials) that are produced in the body and that influences (effects) the way the body grows or develops.
Read the detailed description
Screening Visits
- To see if you are able to take part in this study, you will first have an outpatient visit at the CTRC (Clinical and Translational Research Center). This visit will take about 90 minutes.
- The following tests/procedures will be done at this visit:
- We will ask you about your medical history and past health
- We will give you a physical examination (including digital rectal examination of the prostate gland if you are over the age of 40)
- We will ask you to answer sleep, mood and general health screening questionnaires.
- We will ask you to complete a questionnaire to help us understand how testosterone and other hormones control sexual function and drive.
- We will draw about 1 tablespoon of blood from a needle placed in a vein in your arm for routine safety tests and to check to see if you have any hormonal problems.
- We will give you an ECG (recording of heartbeat). For this test we will attach 12-lead sensors to your chest.
- We will collect urine sample from you for a drug screening test.
- A dietitian will review meal plans for the inpatient stay (Study Visit 1 and 3 only).
If the first screening visit shows that you are able to continue to take part in this study, you will continue the screening part of the study at home. The following will be done at home: We will ask you to undergo an at-home actigraphy and keep a daily sleep diary for two weeks to document your sleeping habits. For the actigraphy you will be asked to wear a small wrist-watch like device. This device will monitor and record your motion, and will also test your sleep and wake periods. It may be worn for up to 2 weeks, 24 hours per day (except while taking a shower).
If the results of the at-home actigraphy show that you are still able to take part in this study, you will continue the final part of the screening procedure which is an inpatient visit to conduct a sleep study. The following tests/procedures will be done for this final screening visit: We will ask you to come into the sleep laboratory to sleep overnight (sleep study). A technician will attach the leads (wires) to your body and you will need to keep these leads on during the night. The attached wires will be connected to a machine to measure chest and abdominal (stomach area) movements, airflow at your mouth and lips, blood oxygen level, muscle tone, eye movements, heart rate and electrical activity of the brain. In the morning, the technician will remove the attached wires.
If the exams, tests and procedures during the screening visits show that you can continue to be in the study, you will have 2 inpatient visits and 2 outpatient clinical visits.
Before beginning the study, we will assign you to one of the two study groups described below. Which one you are assigned to will be decided by chance (like tossing a coin) and you will have a one in two chance of being in any one group. A computer program will place you in one of the study groups.
GROUP 1: If you are assigned to group 1, then you will receive active drug during visit 1 (first inpatient visit) and placebo (inactive drug which is same as receiving no drug) during visit 3 (second inpatient visit). GROUP 2: If you are assigned to group 2, then you will receive placebo (inactive drug which is same as receiving no drug) during visit 1 (first inpatient visit) and active drug for visit 3 (second inpatient visit).
Neither you nor your study doctor can choose the group you will be in. Neither your study doctor or his staff nor you will know which study group or medicine you will be receiving. However should a medical emergency occur, this information will be made immediately available to your study doctor.
During the inpatient visit when you receive active drug, you will receive: Ketoconazole pills. You will swallow these pills every 6 hours (4 times per day). Testosterone gel. You will rub this gel into your skin once a day in the morning. Hydrocortisone pills. You will swallow these pills 3 times a day.
During the inpatient visit when you receive placebo (inactive drug), you will receive:
- Inactive placebo pills (looks like ketoconazole). You will swallow these pills every 6 hours (4 times per day).
- Inactive placebo gel (looks like testosterone gel). You will rub this gel into your skin once a day in the morning.
- Inactive placebo pills (looks like hydrocortisone). You will swallow these pills 3 times a day.
Night before First Inpatient Visit Before coming to the CTRC for your first inpatient visit, you will be asked to sleep 10 hours for two consecutive nights (from 10 PM to 8 AM) at home. During your sleep, you will be wearing an actiwatch to monitor your sleep at home. You cannot drink any alcohol during this 2 day period. We will send you a text message or telephone you to remind you to sleep during these times and not to drink alcohol. The inpatient study visit will be cancelled if you didn't have enough sleep at home or if you consumed alcohol.
Study Visit 1 (First Inpatient) For this visit we will ask you to arrive at the CTRC no later than 5 PM on the first day. We will allow you to go home sometime after lunch after the 5th night. We will give you breakfast, lunch and dinner at set times while you are in the CTRC. The meals are standard, so that what you may have eaten before will not interfere with the study results. The following tests/procedures will be done at this visit: We will download the information from your actiwatch to verify your sleep at home. We will be putting external leads on your body, as occurred during the sleep study, so that we can continuously check your sleep EEG, actiwatch activity and heart rate. We will expose you to dim light (this is so we can measure your "body clock"). From 7 PM until your bedtime every night, saliva will be collected hourly so we can measure your "body clock". We will ask you to fill out a short questionnaire to measure how sleepy you are, how hungry you are and do a computerized test of cognitive function every 2 hours (on odd, not even, hours). This will take about 5 minutes. Starting at 8PM on your first night, urine will collected until 8AM of the following day. This will be repeated every 12-hour period whilst in-lab for measurements of components of in the urine. We will give you an Oral Glucose Tolerance Test (OGTT) in the morning of the first and last days (on two occasions) while you are in the CTRC. The OGTT is the test that measures the body's ability to use a type of sugar, called glucose, which is the body's main source of energy.
- Before the test begins, we will insert a cannula into a vein in your arm and a sample of blood will be taken. The cannula is a small plastic tube through which we will sample your blood. It is inserted over a metal needle into your vein. The metal needle is removed once the cannula is in place.
- We will ask you to drink a liquid that is high in glucose (75 grams).
- In the first hour, we will draw about 5ml (1 teaspoon) of blood will be taken from the cannula every 5 minutes.
- In the second hour, about 5ml (1 teaspoon) of blood will be taken from the cannula every 10 minutes
- In the third hour, about 5ml (1teaspoon) of blood will be taken from the cannula every 20 minutes.
- We will draw an additional 10ml (2 teaspoons) of blood to measure inflammation, hormones, gene expression, and bone metabolism
- The entire test will take about 3 hours.
We will give you an opportunity to sleep before we discharge you and we will test you for sleepiness. Arrangements will be made for you to be driven home if necessary. During this time you cannot drink caffeinated drinks, or use nicotine products.
Study Visit 2 (First Outpatient) This visit will take place one week after you are discharged from your first inpatient visit. At this visit we will ask you about any side effects and draw about 1 tablespoon of blood for complete blood count and routine chemistry check, including liver function tests.
Study Visit 3 (Second Inpatient) This visit will take place one week after your first outpatient visit (about 2 weeks after your first inpatient visit). This visit is identical the first inpatient study Visit 1. For this visit, if you received active study drug during your first inpatient visit, you will receive a placebo. If you received the placebo during the first inpatient study Visit 1, then you will receive active study drug during this visit.
Study Visit 4 (Second Outpatient) This visit will take place one week after you are discharged from your second inpatient visit. At this visit we will ask you about any side effects and draw about 1 tablespoon of blood for complete blood count and routine chemistry check, including liver function tests.
All visits A total of about half a pint (16 tablespoons) of blood will be collected for this study. We will collect less than what you would donate to the blood bank.
- Conditions
- Insulin Resistance
- Being tested
- Ketoconazole, Hydrocortisone, Testosterone, Placebo for ketoconazole, Placebo for hydrocortisone
- Keywords
- Sleep Restriction, Insulin Resistance, Testosterone, Cortisol
- Medical subject headings
- Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
KetoconazoleDrug
Also called Nizoral
Ketoconazole is taken 4 times a day
HydrocortisoneDrug
Also called Cortef, Cortril, Hydrocortone
Hydrocortisone is taken 3 times a day
TestosteroneDrug
Also called AndroGel
Testosterone gel is applied once a day
Placebo for ketoconazoleDrug
Placebo for ketoconazole
Placebo for hydrocortisoneDrug
Placebo for hydrocortisone
Placebo for testosteroneDrug
Placebo for testosterone
| Study group | Role | What they receive |
|---|---|---|
| Placebo and Drug Group 2 | Placebo comparator | Placebo pills and gel is used in place. Placebo for Ketoconazole is taken 4 times a day Placebo for Hydrocortisone is taken 3 times a day Placebo for testosterone gel is applied once a day. Receives: Drug: Ketoconazole; Drug: Hydrocortisone; Drug: Testosterone; Drug: Placebo for ketoconazole; Drug: Placebo for hydrocortisone; Drug: Placebo for testosterone |
| Drug and Placebo Group 1 | Active comparator | Ketoconazole is taken 4 times a day Hydrocortisone is taken 3 times a day Testosterone gel is applied once a day Receives: Drug: Ketoconazole; Drug: Hydrocortisone; Drug: Testosterone; Drug: Placebo for ketoconazole; Drug: Placebo for hydrocortisone; Drug: Placebo for testosterone |
What is being measured
The primary outcome is the main question the study is designed to answer.
Insulin Sensitivity
Insulin sensitivity determined by minimal model of a frequently sampled oral glucose tolerance test (OGTT).This method is extensively validated, and previously utilized by us.
Measured: 3 years
Secondary outcomes (14)
Disposition index
Disposition index (determined by minimal model of the same OGTT)
Measured: 3 years
C-peptide glucose dose-response
C-peptide glucose dose-response (also calculated from the same OGTT)
Measured: 3 years
Lapses on Psychomotor Vigilance Task
Measure of psychomotor performance
Measured: 3 years
Karolinska Sleepiness Scale
Measures sleepiness
Measured: 3 years
Urinary Catecholamines
Measures sympathetic/parasympathetic activity
Measured: 3 years
Heart Rate Variability
Measures sympathetic/parasympathetic activity
Measured: 3 years
Free Fatty Acid Concentrations
Measures potential mediator of insulin resistance
Measured: 3 years
Inflammatory marker panel
blood interleukin-6, sTNFr2, IL1ra, CRP, NFkB concentrations
Measured: 3 years
Computerized cognitive testing
Two card gambling task, modified Sternberg working memory task
Measured: 3 years
Bone turnover panel
P1NP (bone formation marker) and NTX (bone resorption marker)
Measured: 3 years
Food cravings,
Food Craving Index
Measured: 3 years
Assessment of mood states.
Profile of Mood States (POMS)
Measured: 3 years
Food intake
meal and snack consumption calculation
Measured: 3 years
Hunger measurement
Flint visual analogue scale
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Oct 2014 (estimated)
- Study startOct 2014
- Primary completionNov 2017
- Study completionOct 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Insulin ResistanceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Peter y. Liu, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Investigators
- Peter Y Liu, MD PhD, Principal investigator, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02256865
- Sponsor's protocol ID
- 30068-01
- Status last verified
- Sep 2025
- First submitted
- 22 Sep 2014
- Last updated
- 11 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
O'Byrne NA, Yuen F, Niaz W, Liu PY. Sleep and the Testis. Curr Opin Endocr Metab Res. 2021 Jun;18:83-93. doi: 10.1016/j.coemr.2021.03.002. Epub 2021 Mar 11.
PubMed 33937581O'Byrne NA, Yuen F, Butt WZ, Liu PY. Sleep and Circadian Regulation of Cortisol: A Short Review. Curr Opin Endocr Metab Res. 2021 Jun;18:178-186. doi: 10.1016/j.coemr.2021.03.011. Epub 2021 May 5.
PubMed 35128146Liu PY, Lawrence-Sidebottom D, Piotrowska K, Zhang W, Iranmanesh A, Auchus RJ, Veldhuis JD, Van Dongen HPA. Clamping Cortisol and Testosterone Mitigates the Development of Insulin Resistance during Sleep Restriction in Men. J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3436-e3448. doi: 10.1210/clinem/dgab375.
PubMed 34043794Zhang W, Piotrowska K, Chavoshan B, Wallace J, Liu PY. Sleep Duration Is Associated With Testis Size in Healthy Young Men. J Clin Sleep Med. 2018 Oct 15;14(10):1757-1764. doi: 10.5664/jcsm.7390.
PubMed 30353813
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hormonal Mechanisms of Sleep Restriction
- ClinicalTrials.gov ID
- NCT02256865
- Acronym / sponsor ID
- 30068-01
- Conditions
- Insulin Resistance
- Keywords
- Sleep Restriction, Insulin Resistance, Testosterone, Cortisol
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterUniversity, hospital or other
- Study start
- Oct 2014
- Primary completion
- Nov 2017 (actual)
- Study completion
- Oct 2023 (actual)
- First posted
- 6 Oct 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to study the effects of sleep restriction on the production of two hormones, cortisol and testosterone. The investigators aim to show that changing these hormones leads to insulin resistance, which is an important cause of type 2 diabetes mellitus. The investigators may also study the effect of sleep restriction on your food intake and cravings, mood, inflammation, metabolism (including bone), and other hormones. Inflammation is your body's response to stress and injury. Bone metabolism is a process of how your body regenerates (renews) new bone cells and removes old bone cells. Hormones are natural substances (materials) that are produced in the body and that influences (effects) the way the body grows or develops.
Detailed description
Screening Visits
- To see if you are able to take part in this study, you will first have an outpatient visit at the CTRC (Clinical and Translational Research Center). This visit will take about 90 minutes.
- The following tests/procedures will be done at this visit:
- We will ask you about your medical history and past health
- We will give you a physical examination (including digital rectal examination of the prostate gland if you are over the age of 40)
- We will ask you to answer sleep, mood and general health screening questionnaires.
- We will ask you to complete a questionnaire to help us understand how testosterone and other hormones control sexual function and drive.
- We will draw about 1 tablespoon of blood from a needle placed in a vein in your arm for routine safety tests and to check to see if you have any hormonal problems.
- We will give you an ECG (recording of heartbeat). For this test we will attach 12-lead sensors to your chest.
- We will collect urine sample from you for a drug screening test.
- A dietitian will review meal plans for the inpatient stay (Study Visit 1 and 3 only).
If the first screening visit shows that you are able to continue to take part in this study, you will continue the screening part of the study at home. The following will be done at home: We will ask you to undergo an at-home actigraphy and keep a daily sleep diary for two weeks to document your sleeping habits. For the actigraphy you will be asked to wear a small wrist-watch like device. This device will monitor and record your motion, and will also test your sleep and wake periods. It may be worn for up to 2 weeks, 24 hours per day (except while taking a shower).
If the results of the at-home actigraphy show that you are still able to take part in this study, you will continue the final part of the screening procedure which is an inpatient visit to conduct a sleep study. The following tests/procedures will be done for this final screening visit: We will ask you to come into the sleep laboratory to sleep overnight (sleep study). A technician will attach the leads (wires) to your body and you will need to keep these leads on during the night. The attached wires will be connected to a machine to measure chest and abdominal (stomach area) movements, airflow at your mouth and lips, blood oxygen level, muscle tone, eye movements, heart rate and electrical activity of the brain. In the morning, the technician will remove the attached wires.
If the exams, tests and procedures during the screening visits show that you can continue to be in the study, you will have 2 inpatient visits and 2 outpatient clinical visits.
Before beginning the study, we will assign you to one of the two study groups described below. Which one you are assigned to will be decided by chance (like tossing a coin) and you will have a one in two chance of being in any one group. A computer program will place you in one of the study groups.
GROUP 1: If you are assigned to group 1, then you will receive active drug during visit 1 (first inpatient visit) and placebo (inactive drug which is same as receiving no drug) during visit 3 (second inpatient visit). GROUP 2: If you are assigned to group 2, then you will receive placebo (inactive drug which is same as receiving no drug) during visit 1 (first inpatient visit) and active drug for visit 3 (second inpatient visit).
Neither you nor your study doctor can choose the group you will be in. Neither your study doctor or his staff nor you will know which study group or medicine you will be receiving. However should a medical emergency occur, this information will be made immediately available to your study doctor.
During the inpatient visit when you receive active drug, you will receive: Ketoconazole pills. You will swallow these pills every 6 hours (4 times per day). Testosterone gel. You will rub this gel into your skin once a day in the morning. Hydrocortisone pills. You will swallow these pills 3 times a day.
During the inpatient visit when you receive placebo (inactive drug), you will receive:
- Inactive placebo pills (looks like ketoconazole). You will swallow these pills every 6 hours (4 times per day).
- Inactive placebo gel (looks like testosterone gel). You will rub this gel into your skin once a day in the morning.
- Inactive placebo pills (looks like hydrocortisone). You will swallow these pills 3 times a day.
Night before First Inpatient Visit Before coming to the CTRC for your first inpatient visit, you will be asked to sleep 10 hours for two consecutive nights (from 10 PM to 8 AM) at home. During your sleep, you will be wearing an actiwatch to monitor your sleep at home. You cannot drink any alcohol during this 2 day period. We will send you a text message or telephone you to remind you to sleep during these times and not to drink alcohol. The inpatient study visit will be cancelled if you didn't have enough sleep at home or if you consumed alcohol.
Study Visit 1 (First Inpatient) For this visit we will ask you to arrive at the CTRC no later than 5 PM on the first day. We will allow you to go home sometime after lunch after the 5th night. We will give you breakfast, lunch and dinner at set times while you are in the CTRC. The meals are standard, so that what you may have eaten before will not interfere with the study results. The following tests/procedures will be done at this visit: We will download the information from your actiwatch to verify your sleep at home. We will be putting external leads on your body, as occurred during the sleep study, so that we can continuously check your sleep EEG, actiwatch activity and heart rate. We will expose you to dim light (this is so we can measure your "body clock"). From 7 PM until your bedtime every night, saliva will be collected hourly so we can measure your "body clock". We will ask you to fill out a short questionnaire to measure how sleepy you are, how hungry you are and do a computerized test of cognitive function every 2 hours (on odd, not even, hours). This will take about 5 minutes. Starting at 8PM on your first night, urine will collected until 8AM of the following day. This will be repeated every 12-hour period whilst in-lab for measurements of components of in the urine. We will give you an Oral Glucose Tolerance Test (OGTT) in the morning of the first and last days (on two occasions) while you are in the CTRC. The OGTT is the test that measures the body's ability to use a type of sugar, called glucose, which is the body's main source of energy.
- Before the test begins, we will insert a cannula into a vein in your arm and a sample of blood will be taken. The cannula is a small plastic tube through which we will sample your blood. It is inserted over a metal needle into your vein. The metal needle is removed once the cannula is in place.
- We will ask you to drink a liquid that is high in glucose (75 grams).
- In the first hour, we will draw about 5ml (1 teaspoon) of blood will be taken from the cannula every 5 minutes.
- In the second hour, about 5ml (1 teaspoon) of blood will be taken from the cannula every 10 minutes
- In the third hour, about 5ml (1teaspoon) of blood will be taken from the cannula every 20 minutes.
- We will draw an additional 10ml (2 teaspoons) of blood to measure inflammation, hormones, gene expression, and bone metabolism
- The entire test will take about 3 hours.
We will give you an opportunity to sleep before we discharge you and we will test you for sleepiness. Arrangements will be made for you to be driven home if necessary. During this time you cannot drink caffeinated drinks, or use nicotine products.
Study Visit 2 (First Outpatient) This visit will take place one week after you are discharged from your first inpatient visit. At this visit we will ask you about any side effects and draw about 1 tablespoon of blood for complete blood count and routine chemistry check, including liver function tests.
Study Visit 3 (Second Inpatient) This visit will take place one week after your first outpatient visit (about 2 weeks after your first inpatient visit). This visit is identical the first inpatient study Visit 1. For this visit, if you received active study drug during your first inpatient visit, you will receive a placebo. If you received the placebo during the first inpatient study Visit 1, then you will receive active study drug during this visit.
Study Visit 4 (Second Outpatient) This visit will take place one week after you are discharged from your second inpatient visit. At this visit we will ask you about any side effects and draw about 1 tablespoon of blood for complete blood count and routine chemistry check, including liver function tests.
All visits A total of about half a pint (16 tablespoons) of blood will be collected for this study. We will collect less than what you would donate to the blood bank.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo and Drug Group 2 | Placebo comparator | Drug: Ketoconazole, Drug: Hydrocortisone, Drug: Testosterone, Drug: Placebo for ketoconazole, Drug: Placebo for hydrocortisone, Drug: Placebo for testosteronePlacebo pills and gel is used in place. Placebo for Ketoconazole is taken 4 times a day Placebo for Hydrocortisone is taken 3 times a day Placebo for testosterone gel is applied once a day. |
| Drug and Placebo Group 1 | Active comparator | Drug: Ketoconazole, Drug: Hydrocortisone, Drug: Testosterone, Drug: Placebo for ketoconazole, Drug: Placebo for hydrocortisone, Drug: Placebo for testosteroneKetoconazole is taken 4 times a day Hydrocortisone is taken 3 times a day Testosterone gel is applied once a day |
Who may qualify
- Ages
- 22 to 45 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Men aged 22-45 years
- Willingness to provide written informed consent
- Stable weight over preceding 6 weeks
- Body Mass index (BMI) 20-28 kg/m2
Key exclusion criteria (19 listed)
- Unable or unwilling to provide IRB-approved informed consent
- Clinical disorders and/or illnesses
- Current medical or drug treatment, as assessed by questionnaire
- History of brain injury or of learning disability
- Vision or hearing impairment unless corrected back to normal
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| KetoconazoleAlso: NizoralKetoconazole is taken 4 times a day | Drug | Drug and Placebo Group 1, Placebo and Drug Group 2 |
| HydrocortisoneAlso: Cortef, Cortril, HydrocortoneHydrocortisone is taken 3 times a day | Drug | Drug and Placebo Group 1, Placebo and Drug Group 2 |
| TestosteroneAlso: AndroGelTestosterone gel is applied once a day | Drug | Drug and Placebo Group 1, Placebo and Drug Group 2 |
| Placebo for ketoconazolePlacebo for ketoconazole | Drug | Drug and Placebo Group 1, Placebo and Drug Group 2 |
| Placebo for hydrocortisonePlacebo for hydrocortisone | Drug | Drug and Placebo Group 1, Placebo and Drug Group 2 |
| Placebo for testosteronePlacebo for testosterone | Drug | Drug and Placebo Group 1, Placebo and Drug Group 2 |
Primary outcome
Insulin Sensitivity
Time frame: 3 years
Insulin sensitivity determined by minimal model of a frequently sampled oral glucose tolerance test (OGTT).This method is extensively validated, and previously utilized by us.
14 secondary outcomes
Disposition index
Time frame: 3 years
C-peptide glucose dose-response
Time frame: 3 years
Lapses on Psychomotor Vigilance Task
Time frame: 3 years
Karolinska Sleepiness Scale
Time frame: 3 years
Urinary Catecholamines
Time frame: 3 years
Heart Rate Variability
Time frame: 3 years
Free Fatty Acid Concentrations
Time frame: 3 years
Inflammatory marker panel
Time frame: 3 years
Computerized cognitive testing
Time frame: 3 years
Bone turnover panel
Time frame: 3 years
Food cravings,
Time frame: 3 years
Assessment of mood states.
Time frame: 3 years
Food intake
Time frame: 3 years
Hunger measurement
Time frame: 3 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2025.
- Background: PubMed 33937581O'Byrne NA, Yuen F, Niaz W, Liu PY. Sleep and the Testis. Curr Opin Endocr Metab Res. 2021 Jun;18:83-93. doi: 10.1016/j.coemr.2021.03.002. Epub 2021 Mar 11.
- Background: PubMed 35128146O'Byrne NA, Yuen F, Butt WZ, Liu PY. Sleep and Circadian Regulation of Cortisol: A Short Review. Curr Opin Endocr Metab Res. 2021 Jun;18:178-186. doi: 10.1016/j.coemr.2021.03.011. Epub 2021 May 5.
- Results publication: PubMed 34043794Liu PY, Lawrence-Sidebottom D, Piotrowska K, Zhang W, Iranmanesh A, Auchus RJ, Veldhuis JD, Van Dongen HPA. Clamping Cortisol and Testosterone Mitigates the Development of Insulin Resistance during Sleep Restriction in Men. J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3436-e3448. doi: 10.1210/clinem/dgab375.
- Derived from this study: PubMed 30353813Zhang W, Piotrowska K, Chavoshan B, Wallace J, Liu PY. Sleep Duration Is Associated With Testis Size in Healthy Young Men. J Clin Sleep Med. 2018 Oct 15;14(10):1757-1764. doi: 10.5664/jcsm.7390.
- Individual participant dataSharing planned: No
Related trials for Insulin Resistance
Not yet recruitingPhase 2
Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity
Insulin Resistance, Obesity
Recruiting
Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
Healthy Volunteer
Recruiting
Improving Sleep Health and Circadian Timing to Support Cardiometabolic Health in Adolescents
Overweight Adolescents, Sleep
RecruitingObservational study
Food-i-Sense Analytics: Integrating AI Into Continuous Glucose Monitoring Data Analysis for Precision Nutrition.
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Artificial Intelligence Mobile Application
RecruitingPhase 3
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Peter Y Liu, MD PhD principal investigator
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Ketoconazole, Hydrocortisone and Testosterone in people with Insulin Resistance, run by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Insulin Sensitivity (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02256865, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2025; AzTrials last refreshed its copy on 6 Nov 2026.